Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid

FREE Breaking News Alerts from StreetInsider.com!

More News related to TEVA

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences
Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer

More News related to FDA

November 10, 2009 4:28 PM EST

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. Customers will begin receiving product on November 11, 2009.

Annual sales of Prevacid Delayed-Release Capsules were approximately $2.97 billion in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.